In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 350+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer. A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells.

Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies.

Apoptopic Agents Highlights

- In-depth competitive landscape assessment of the apoptopic market in oncology

- Thorough review of utilized targets in apoptopic drug development

- Thorough review of approved drugs

- Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls

- Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic spread or not. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector mechanisms (vaccines).

Immunotherapy in Highlights

- In-depth competitive landscape assessment of the cancer immunotherapy market place; Including more than 200 immunotherapy drugs and pharmaceutical companies

- Thorough review of tumor antigen discovery, immunomodulating strategies and adjuvants

- Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation

- Progress analysis of six major cancer vaccine indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls

Topics Covered

1 Executive Summary

2 Table of Contents

3 Methodology

4 Introduction to Apoptosis in Oncology

5 Apoptosis Competitive Landscape in Oncology

6 Approved Apoptopic Cancer Drugs: Performance

7 Target Analysis in Apoptosis

8 Apoptopic Drugs in Development: By Major Indications

9 Immunotherapy in Oncology

10 Competitive Landscape in Cancer Vaccines

11 Antibody Deals on the Rise

12 Tumor Antigens

13 Immunomodulators & Adjuvants in Cancer Vaccines

14 Cancer Vaccine Delivery

15 New Approaches in Antibody Delivery and Design - The Next Generation

16 Cancer Vaccines in Development: By Major Indications

17 Antibodies in Clinical Development

18 Disclaimer

19 Company Index

20 Drug Index

21 List of Boxes

22 List of Figures

23 List of Tables